Brandsteterová E, Kelner M J, McMorris T C, Estes L, Bagnell R, Montoya M
Department of Analytical Chemistry, Slovak Technical University, Bratislava.
Neoplasma. 1992;39(6):369-73.
High performance liquid chromatography (HPLC) combined with effective preseparation steps (liquid extraction, solid-phase extraction, preconcentration procedures) was used in pharmacokinetic studies of a novel anticancer agent (acylfulvene) in serum. HPLC conditions were optimized for the analysis of model clinical samples and real serum samples with different contents of acylfulvene. Extraction recoveries for both extraction procedures were evaluated and linearity was achieved for a wide concentration range. Detection limit for acylfulvene in serum was 0.075 microgram/ml, preconcentration minimum 5 times was recommended, especially after the solid-phase extraction step. The HPLC assay was applied for pharmacokinetic studies of acylfulvene in dogs and rats and pharmacokinetic parameters were determined.
高效液相色谱法(HPLC)结合有效的预分离步骤(液液萃取、固相萃取、预富集程序)用于新型抗癌药物(酰基富烯)在血清中的药代动力学研究。针对含有不同酰基富烯含量的模型临床样本和实际血清样本的分析,对HPLC条件进行了优化。评估了两种萃取程序的萃取回收率,并在较宽的浓度范围内实现了线性关系。血清中酰基富烯的检测限为0.075微克/毫升,建议至少进行5倍预富集,尤其是在固相萃取步骤之后。该HPLC测定法应用于酰基富烯在犬和大鼠体内的药代动力学研究,并测定了药代动力学参数。